Sign in →

Test ID P53 p53 Immunostain, Technical Component Only


Ordering Guidance


This test includes only technical performance of the stain (no pathologist interpretation is performed). If diagnostic consultation by a pathologist is required order PATHC / Pathology Consultation.



Shipping Instructions


Attach the green pathology address label and the pink Immunostain Technical Only label included in the kit to the outside of the transport container.



Specimen Required


Supplies: Immunostain Technical Only Envelope (T693)

Specimen Type: Tissue

Container/Tube: Immunostain Technical Only Envelope

Preferred: 2 Unstained positively charged glass slide (25- x 75- x 1-mm) per test ordered; sections 4-microns thick

Acceptable: Formalin-fixed, paraffin-embedded (FFPE) tissue block


Useful For

Aiding in the identification of neoplastic cells

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
IHTOI IHC Initial, Tech Only No No
IHTOA IHC Additional, Tech Only No No

Method Name

Immunohistochemistry (IHC)

Reporting Name

p53 IHC, Tech Only

Specimen Type

TECHONLY

Specimen Stability Information

Specimen Type Temperature Time Special Container
TECHONLY Ambient (preferred)
  Refrigerated 

Clinical Information

p53 is a tumor-suppressor protein. Genetic events (variant and deletion) that affect both P53 alleles can lead to loss of cell cycle control in the setting of DNA damage, resulting in genetic instability and neoplastic transformation. Altered p53 also has a prolonged half-life compared to wildtype p53 and, thus, accumulates in the nucleus and can be detected by immunohistochemistry. Abnormalities of the P53 gene are one of the most common genetic changes associated with cancer and can be found in a wide variety of tumor types, where they are generally associated with a worse prognosis. The p53 protein can be readily detected in a subset of cancers of the colon, stomach, bladder, breast, lung, and testes and in melanoma and lymphoma.

Interpretation

This test does not include pathologist interpretation, only technical performance of the stain. If interpretation is required, order PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case.

 

The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request, call 855-516-8404.

 

Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Clinical Reference

1. Bartley AN, Ross DW: Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice. Arch Pathol Lab Med. 2002 Apr;126(4):456-458

2. Camelo-Piragua S, Jansen M, Ganguly A, et al: A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neropathol Exp Neurol. 2011 Feb;70(2):110-115

3. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer. 1995 Oct 1;76(7):1201-1208

4. Mayall FG, Goddard H, Gibbs AR: p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):377-381

5. van den Berg FM, Baas IO, Polak MM, Offerhaus GJ: Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol. 1993 Feb;142(2)381-385

6. Zarei S, Wang Y, Jenkins SM, Voss JS, Kerr SE, Bell DA: Clinicopathologic, immunohistochemical, and molecular characteristics of ovarian serous carcinoma with mixed morphologic features of high-grade and low-grade serous carcinoma. Am J Surg Pathol. 2020 Mar;44(3):316-328. doi: 10.1097/PAS.0000000000001419

Day(s) Performed

Monday through Friday

Report Available

1 to 3 days

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

88342-TC, primary

88341-TC, if additional IHC

LOINC Code Information

Test ID Test Order Name Order LOINC Value
P53 p53 IHC, Tech Only Order only;no result

 

Result ID Test Result Name Result LOINC Value
70840 p53 IHC, Tech Only Bill only; no result

Forms

If not ordering electronically, complete, print, and send a Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763) with the specimen.

Disease States

  • Breast cancer
Mayo Clinic Laboratories | IHC Catalog Additional Information:

mcl-ihc